All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...
The move comes as the company faces ‘several challenges’ around the launching of medicines and timed out patents ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
The launch of My Green Lab Certification 2.0 introduces enhanced tools and resources to drive measurable impact in ...
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...
AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.
Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...
Zacks.com on MSN1d
Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings?AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...
Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback